Sparking Transformation in Healthcare
egnite is a technology company advancing guideline-directed cardiovascular care and real-world evidence.
Sparking Transformation in Healthcare
egnite is a company with a vision:
to identify and improve outcomes for every cardiovascular patient in the U.S.
Sparking Transformation in Healthcare
egnite is a company with a vision:
to identify and improve outcomes for every cardiovascular patient in the U.S.
TURNING DATA INTO CLINICAL ACTION & iNSIGHTS 
egnite's CardioCare + Registry
The CardioCare® platform is deployed at more than 80 heart programs to identify and prioritize cardiovascular patients. The egnite Registry, built on de-identified EHR data, gives life sciences and research teams a longitudinal view of the patient journey. FOR CLINICIANS
The CardioCare Platform
by artificial intelligence
FOR LIFE SCIENCES 
egnite Therapy Accelerator & Research
of real-world cardiovascular data
Podcasts
egnite COO, Jessica Neufeld, discusses the current state of A.I. adoption and challenges in healthcare, along with the role of technology in improving patient care on a recent episode of Microsoft’s Data and A.I. podcast Insights Tomorrow.
egnite Senior Medical Advisor, Rahul Sharma, was recently featured on MedAxiom’s HeartTalk podcast to discuss how technology can be used to identify and treat patients before it’s too late.
Learn more from egnite CEO, Joel Portice, on how egnite is elevating the role of A.I. and big data to guide critical decisions in healthcare on Mike Moore’s The Bleeding Edge of Digital Health podcast.
Real-World Evidence
Presented or Published in
Recognition
Testimonials
Leading health systems and life sciences organizations partner with egnite to transform care delivery for cardiovascular patients.
Gagnon Cardiovascular Institute, Morristown Medical Center
Director of Structural Interventions, Stanford Health Care
Senior Medical Advisor, egnite
Resources
Real-world data from 47 U.S. health systems shows three-year survival of 76% among systolic heart failure patients prescribed four GDMT classes, versus 52% among those
The egnite Registry contributed de-identified, longitudinal data, linking serial echocardiograms with clinical outcomes, to help answer what happens to patients after a successful mitral transcatheter edge-to-edge repair (M-TEER) procedure. ALISO VIEJO,
BACKGROUND Aortic stenosis (AS) and mitral regurgitation (MR) frequently co-occur, complicating diagnosis and treatment. We examined current US treatment trends and patient outcomes among patients